← Back to guidelines
Dermatology60 papers

Albinism with deafness syndrome

Last edited: 4/14/2026

Overview

Albinism with deafness syndrome encompasses genetic disorders characterized by a lack of melanin production affecting skin, hair, and eyes, often accompanied by sensorineural deafness. This condition presents significant ophthalmologic and audiologic challenges 4.

Diagnosis

  • Ophthalmologic Evaluation: Assess visual acuity, refractive errors, nystagmus, and strabismus 1.
  • Genetic Testing: Identify specific subtypes (OCA1, OCA2, OCA4) through genetic analysis 1.
  • Audiological Assessment: Conduct comprehensive hearing tests to confirm sensorineural deafness 4.
  • Vitamin D Levels: Measure serum 25-hydroxyvitamin D (25[OH]D) levels, especially considering sun avoidance behavior 2.
  • Management

  • Ophthalmic Interventions: Correct refractive errors with glasses or contact lenses; consider strabismus surgery if amblyopia or significant diplopia 1.
  • Hearing Aids/Devices: Utilize appropriate hearing aids or cochlear implants for managing sensorineural deafness 4.
  • Vitamin D Supplementation: Monitor and supplement vitamin D levels as needed, particularly in populations with high sun avoidance 2.
  • Educational Support: Provide tailored educational support considering communication needs and visual assessment challenges 4.
  • Special Populations

  • Pediatric Considerations: Early intervention for visual and auditory impairments is crucial 4.
  • Sun Protection: Emphasize strict sun protection measures due to increased risk of skin damage 2.
  • Key Recommendations

  • Perform comprehensive ophthalmologic evaluations including visual acuity, refractive errors, and genetic testing to subtype albinism 1 (Evidence: Moderate).
  • Regular audiological assessments are essential for early detection and management of sensorineural deafness 4 (Evidence: Moderate).
  • Monitor and manage vitamin D levels due to potential deficiency risks associated with sun avoidance 2 (Evidence: Moderate).
  • References

    1 Seguy PH, Korobelnik JF, Delyfer MN, Michaud V, Arveiler B, Lasseaux E et al.. Ophthalmologic Phenotype-Genotype Correlations in Patients With Oculocutaneous Albinism Followed in a Reference Center. Investigative ophthalmology & visual science 2023. link 2 Van der Walt JE, Sinclair W. Vitamin D levels in patients with albinism compared with those in normally pigmented Black patients attending dermatology clinics in the Free State province, South Africa. International journal of dermatology 2016. link 3 Gottlob I. Albinism: a model of adaptation of the brain in congenital visual disorders. The British journal of ophthalmology 2007. link 4 Hyvärinen L. Implications of deafblindness on visual assessment procedures: considerations for audiologists, ophthalmologists, and interpreters. Trends in amplification 2007. link 5 Branford WA. Hutchinson and Nettleship, Nettlerash and albinism. The British journal of dermatology 2000. link 6 James T. Curiosa paediatrica VIII: Infans bicolor. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1984. link 7 Chian LT, Wilgram GF. Tyrosinase inhibition: its role in suntanning and in albinism. Science (New York, N.Y.) 1967. link

    Original source

    1. [1]
      Ophthalmologic Phenotype-Genotype Correlations in Patients With Oculocutaneous Albinism Followed in a Reference Center.Seguy PH, Korobelnik JF, Delyfer MN, Michaud V, Arveiler B, Lasseaux E et al. Investigative ophthalmology & visual science (2023)
    2. [2]
    3. [3]
      Albinism: a model of adaptation of the brain in congenital visual disorders.Gottlob I The British journal of ophthalmology (2007)
    4. [4]
    5. [5]
      Hutchinson and Nettleship, Nettlerash and albinism.Branford WA The British journal of dermatology (2000)
    6. [6]
      Curiosa paediatrica VIII: Infans bicolor.James T South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (1984)
    7. [7]
      Tyrosinase inhibition: its role in suntanning and in albinism.Chian LT, Wilgram GF Science (New York, N.Y.) (1967)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG